Maat Pharma SA - Asset Resilience Ratio
Maat Pharma SA (MAAT) has an Asset Resilience Ratio of 0.06% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Maat Pharma SA balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how Maat Pharma SA's Asset Resilience Ratio has changed over time. See Maat Pharma SA shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Maat Pharma SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MAAT stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €31.00K | 0.06% |
| Total Liquid Assets | €31.00K | 0.06% |
Asset Resilience Insights
- Limited Liquidity: Maat Pharma SA maintains only 0.06% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Maat Pharma SA Industry Peers by Asset Resilience Ratio
Compare Maat Pharma SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Maat Pharma SA (2022–2024)
The table below shows the annual Asset Resilience Ratio data for Maat Pharma SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 22.75% | €8.76 Million ≈ $10.24 Million |
€38.50 Million ≈ $45.01 Million |
-22.54pp |
| 2023-12-31 | 45.29% | €19.44 Million ≈ $22.73 Million |
€42.93 Million ≈ $50.19 Million |
+3.69pp |
| 2022-12-31 | 41.60% | €18.61 Million ≈ $21.75 Million |
€44.73 Million ≈ $52.29 Million |
-- |
About Maat Pharma SA
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improve… Read more